OncoMatch/Clinical Trials/NCT03185468

Intervention of Bladder Cancer by CAR-T

Is NCT03185468 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for bladder cancer.

Phase 1/2RecruitingShenzhen Geno-Immune Medical InstituteNCT03185468Data as of May 2026

This is a Phase I/II and multicenter study designed to evaluate the efficacy and safety of 4SCAR-T cells in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have no further treatment available.

Check if I qualify

Extracted eligibility criteria

Cancer type

Urothelial Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: any approved anti-cancer therapy

Cannot have received: investigational agent

Lab requirements

Blood counts

Adequate hematologic function

Kidney function

Adequate end organ function

Liver function

Adequate end organ function

Adequate hematologic and end organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify